Gapping up
In reaction to strong earnings/guidance:
- MNST +13.7%, ONP +10.6%, NVGS +9.1%, CWST +6.9%, FOXF +6.8%, PEIX +6.6%, BLDP +6.5%, WTI +6.1%
- AMRC +5.8%, GKOS +5.4%, AVGO +5.3%, SSH +5.1%, JD +4.8%, ANF +4.5%, HIIQ +3.6%, BURL +3.2%, EPE +3.1%
- ALIM +3%, ANW +2.9%, HDSN +2.4%, ASM +2.3%, WSR +2.1%, ACIW +2%, AJRD +1.9%, JCAP +1.1%
Other news:
- AUPH +65.2% (announces its Phase IIb AURA-LV study in lupus nephritis met the complete and partial remission ("CR"/ "PR") endpoints at 48 weeks; AURORA Phase III trial with low dose voclosporin on track to commence in 2Q17)
- ALQA +12.7% ( Celgene [CELG] increases active stake to 22.2% (Prior 15.9%) -- Celgene purchased 4 mln shares in ALQA's 2/27 private placement)
- VRML +10.6% (announces a contracted agreement with Blue Cross Blue Shield of Michigan for OVA1)
- EXAS +7.7% (EXACT Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test),
- KAO +2.5% (reviews its R&D Day agenda; Plazomicin NDA submission planned for the second half of 2017 )
- CAMT +2.5% ( announces that 'one of the world's leading CMOS Image Sensor manufacturers' placed multiple orders for inspection and metrology systems)
- VRX +1.6% ( corrects 'misleading report about Salix investigation' )
Analyst comments:
- SRPT +4.3% (upgraded to Outperform at Leerink Partners)
- ARMK +2.7% (added to Conviction Buy List at Goldman)